Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
19 Aug 2022
19 Aug 2022
Historique:
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Consecutive waves of SARS-CoV-2 infection have been driven in part by the repeated emergence of variants with mutations that confer resistance to neutralizing antibodies Nevertheless, prolonged or repeated antigen exposure generates diverse memory B-cells that can produce affinity matured receptor binding domain (RBD)-specific antibodies that likely contribute to ongoing protection against severe disease. To determine how SARS-CoV-2 omicron variants might escape these broadly neutralizing antibodies, we subjected chimeric viruses encoding spike proteins from ancestral, BA.1 or BA.2 variants to selection pressure by a collection of 40 broadly neutralizing antibodies from individuals with various SARS-CoV-2 antigen exposures. Notably, pre-existing substitutions in the BA.1 and BA.2 spikes facilitated acquisition of resistance to many broadly neutralizing antibodies. Specifically, selection experiments identified numerous RBD substitutions that did not confer resistance to broadly neutralizing antibodies in the context of the ancestral Wuhan-Hu-1 spike sequence, but did so in the context of BA.1 and BA.2. A subset of these substitutions corresponds to those that have appeared in several BA.2 daughter lineages that have recently emerged, such as BA.5. By including as few as 2 or 3 of these additional changes in the context of BA.5, we generated spike proteins that were resistant to nearly all of the 40 broadly neutralizing antibodies and were poorly neutralized by plasma from most individuals. The emergence of omicron variants has therefore not only allowed SARS-CoV-2 escape from previously elicited neutralizing antibodies but also lowered the genetic barrier to the acquisition of resistance to the subset of antibodies that remained effective against early omicron variants.
Identifiants
pubmed: 36032981
doi: 10.1101/2022.08.17.504313
pmc: PMC9413706
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : P01 AI165075
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI078788
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI064003
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI111825
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Elife. 2020 Oct 28;9:
pubmed: 33112236
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
Viruses. 2022 Jun 18;14(6):
pubmed: 35746806
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Cell. 2020 Nov 25;183(5):1298-1311.e11
pubmed: 33125897
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Open Forum Infect Dis. 2022 May 07;9(7):ofac227
pubmed: 35818364
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Sci Immunol. 2022 Jul 29;7(73):eabq3511
pubmed: 35549299
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
Nature. 2022 Apr;604(7906):553-556
pubmed: 35240676
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Cell Rep. 2021 Sep 28;36(13):109760
pubmed: 34534459
Nat Med. 2022 Jun 27;:
pubmed: 35760080
Immunity. 2022 Aug 9;55(8):1501-1514.e3
pubmed: 35777362
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
Nature. 2021 Dec;600(7889):512-516
pubmed: 34544114
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194